2014 Opportunities in the UK Clinical Chemistry and Immunodiagnostic Market is a new strategic analysis of major business opportunities emerging in the UK clinical chemistry and immunodiagnostic markets during the nextfive years. The report explores future trends in the UK market; provides estimates of the specimen, test and sales volumes, as well as major suppliers sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years. Research Beam Model: Research Beam Product ID: 174918 3950 USD New
2014-2018 UK Clinical Chemistry and Immunodiagnostic Markets: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies

Toll Free : +1 (800)910-6452

 
 
PURCHASE OPTIONS
 

2014-2018 UK Clinical Chemistry and Immunodiagnostic Markets: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies

 
  • Category : Diagnostic and Biotech
  • Published On : November  2014
  • Pages : 563
 
 

2014 Opportunities in the UK Clinical Chemistry and Immunodiagnostic Market is a new strategic analysis of major business opportunities emerging in the UK clinical chemistry and immunodiagnostic markets during the nextfive years. The report explores future trends in the UK market; provides estimates of the specimen, test and sales volumes, as well as major suppliers sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.



The report provides five-year volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in hospitals, commercial laboratories, physician offices, and ambulatory care centers, including controls, calibrators and consumables.



Rationale



The clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, are already resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.



Strategic Recommendations



- New product development opportunities

with significant market appeal.



- Alternative market penetration strategies.



- Potential market entry barriers and risks.



Competitive Assessments



- Strategic assessments of major suppliers and

emerging market entrants, including their sales, product

portfolios, marketing tactics, collaborative

arrangements and new products in. 



- The companies analyzed in the report include

Abbott, AdnaGen, Agilent, Alere, Beckman Coulter/Danaher,

Biomedical Diagnostics, bioMerieux, Bio-Rad, DiaSorin,

Eiken, Fujirebio/Innogenetics, IL, Kyowa Medex,

Ortho-Clinical Diagnotics, Roche, Siemens, Sysmex,

Thermo Fisher, Tosoh, Wako, Wallac/PE.



Tests Analyzed in the Report:



Routine Clinical Chemistry



Albumin, Alkaline Phosphatase, ALT/SGPT, Ammonia, Amylase, AST/SGOT, Bilirubin, Total,

BUN (Blood Urea Nitrogen), Calcium, Cardio CRP, Carbon Dioxide/Bicarbonate, Chloride,

Cholesterol, Creatine Kinase (CK), CK-MB, Creatinine, CRP, Ferritin, GGT, Glucose,

HDL Cholesterol, Homocysteine, Iron, LDH, LDL Cholesterol, Magnesium, Phosphorus,

Potassium, Protein, Total, Sodium, Triglycerides, Troponin, Uric Acid. 



Therapeutic Drug Monitoring (TDM)



Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam,

Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Sirolimus,

Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vancomycin.



Endocrine Function



Cortisol, Estradiol, FSH, HCG, Gastrin, LH, Progesterone, PTH/IO PTH,

Prolactin, T3, T3 Uptake, Free T3, T4, Free T4, TBG, Testosterone,

Thyroglobulin Ab, TPO Ab, TSH.



Tumor Markers and Special Chemistry



AFP, CA 15-3/27-29, CA 19-9, CEA, Ferritin, Follate (Folic Acid),

Glycosylated Hemoglobin, HCG, 25-Hydroxy Vitamin D2 and D3, Occult Blood,

PAP, PSA, Thyroglobulin, Vitamin B-12.



Immunoproteins



C3, C4, Free Light Chains, Haptoglobin, IgA, IgE Specific, IgE Total, IgG, IgM,

Immunofixation, Prealbumin, Protein Electrophoresis.



Drugs of Abuse



Amphetamines, Barbiturates, Benzodiazepines, Cannabinoids/Marijuana, Cocaine,

LSD, Methadone, Methaqualone, Opiates, Phencyclidine (PCP),

Propoxyphene, Tricyclic Antidepressants.



Market Segmentation Analysis



- Comprehensive review of the market

dynamics, trends, structure, size, growth,

and key suppliers.



- Test volume and sales forecasts for over 100 clinical chemistry,

TDM, endocrine, cancer, immunoprotein and abused drug assays,

by market segment:



° Hospitals

° Commercial/Private Laboratories



Current and Emerging Products



- Analysis of current and emerging clinical chemistry

and immunodiagnostic tests.



- Review of current instrumentation technologies, and feature comparison

of high-, medium-, and low-volume/POC analyzers.



Technology Review



- Assessment of current and emerging

technologies, and their potential market applications.



- Comprehensive lists of companies developing

or marketing new technologies and products by test.



Contains 563 pages and 103 tables